Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2Phase 1 2Phase EARLY_PHASE1 1Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 5Vomiting 1Renal Insufficiency 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polycystic Ovary Syndrome 1Plasmacytoma 1POEMS Syndrome 1Obesity 1Neurotoxicity Syndromes 1Neoplasms, Plasma Cell 1Neoplasm Metastasis 1Nausea 1Lymphoma, T-Cell, Peripheral 1Lymphoma, B-Cell 1Lymphoma 1Leukemia, Large Granular Lymphocytic 1Immunoglobulin Light-chain Amyloidosis 1Brain Neoplasms 1Amyloidosis 1Alzheimer Disease 1

Interventions

ixazomib 1dexamethasone acetate 1dexamethasone 21-phosphate 1auricularum 1Lenalidomide 1Dexamethasone 1Calcium Dobesilate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Plasmacytoma × Dexamethasone × Clear all
NCT02921893 2025-02-12

Ixazomib Citrate, Lenalidomide, and Dexamethasone in Treating Patients With POEMS Syndrome

Mayo Clinic

Phase EARLY_PHASE1 Completed
21 enrolled
Plasma cell

Plasmacytoma, POEMS Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡